



Brexafemme® (ibrexafungerp) – New drug approval

- On June 2, 2021, [SCYNEXIS announced](#) the FDA approval of [Brexafemme \(ibrexafungerp\)](#), for the treatment of adult and post-menarchal pediatric females with vulvovaginal candidiasis (VVC).
- VVC, commonly known as a vaginal yeast infection due to *Candida*, is the second most common cause of vaginitis. An estimated 70 to 75% of women worldwide will have at least one episode of VVC in their lifetime, and 40 to 50% of them will experience multiple episodes.
- Brexafemme is a novel triterpenoid antifungal drug.
- The efficacy of Brexafemme was established in two randomized, placebo-controlled studies with a similar design in non-pregnant post-menarchal females with VVC. Study 1 included 290 patients and study 2 included 278 patients. Efficacy was assessed by clinical outcome at the test of cure (TOC) visit. A complete clinical response was defined as the complete resolution of signs and symptoms.
 - In study 1, complete clinical response at TOC was achieved in 50.0% of patients treated with Brexafemme vs. 28.0% of patients treated with placebo (difference of 22.0, 95% CI: 10.2, 32.8; $p = 0.001$).
 - In study 2, complete clinical response at TOC was achieved in 63.5% of patients treated with Brexafemme and 44.9% of patients treated with placebo (difference of 18.6, 95% CI: 6.0, 30.6; $p = 0.009$).
- Brexafemme is contraindicated in pregnancy and in patients with hypersensitivity to ibrexafungerp.
- A warnings and precaution for Brexafemme is risk of fetal toxicity.
- The most common adverse reactions ($\geq 2\%$) with Brexafemme use were diarrhea, nausea, abdominal pain, dizziness, and vomiting.
- The recommended dose of Brexafemme is 300 mg (two 150 mg tablets) administered approximately 12 hours apart (eg, in the morning and in the evening) for one day, for a total daily dosage of 600 mg (four 150 mg tablets).
- SCYNEXIS plans to launch Brexafemme in the second half of 2021. Brexafemme will be available as a 150 mg tablet.



OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at [optum.com](#).

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2021 Optum, Inc. All rights reserved.